Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
Status:
Completed
Trial end date:
2004-12-16
Target enrollment:
Participant gender:
Summary
The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment
with rosiglitazone/metformin will safely and effectively control glycemia as first line oral
therapy in subjects type 2 diabetes. The primary objective of the study is to demonstrate
superiority of rosiglitazone/metformin compared to its rosiglitazone and metformin.